Clinical and laboratory indicators of polycystic ovary syndrome in Chinese Han nationality with different Rotterdam criteria-based phenotypes

References

• Stein I, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181–91
   Google Scholar
• Zhao Y, Du B, Jiang X, et al. Effects of combining low-dose aspirin with a Chinese patent medicine on follicular blood flow and pregnancy outcome. Mol Med Rep 2014;10:2372–6
   PubMed Web of Science ®Google Scholar
• Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012;97:28–38
   PubMed Web of Science ®Google Scholar
• Mes-Krowinkel MG, Louwers YV, Mulders AG, et al. Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients. Fertil Steril 2014;101:1757–65.e1
   PubMed Web of Science ®Google Scholar
• Kim JJ, Hwang KR, Choi YM, et al. Complete phenotypic and metabolic profiles of a large consecutive cohort of untreated Korean women with polycystic ovary syndrome. Fertil Steril 2014;101:1424–30
   PubMed Web of Science ®Google Scholar
• Hudecova M, Jan H, Christian B, Poromaa Inger S. Long-term reproductive and metabolic consequences of PCOS. Curr Diabetes Rev 2012;8:444–51
   PubMedGoogle Scholar
• Roe AH, Prochaska E, Smith M, et al. Using the androgen excess PCOS society criteria to diagnosepolycystic ovary syndrome and the risk of metabolic syndrome in adolescents. J Pediatr 2013;162:937–41
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHER/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus of diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, et al. Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237–45
   PubMed Web of Science ®Google Scholar
• Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007;66:513–17
   PubMed Web of Science ®Google Scholar
• Rehme MF, Pontes AG, Corrente JE, et al. Contribution of hyperandrogenism to the development of metabolic syndrome in obese women with polycystic ovary syndrome. Rev Bras Ginecol Obstet 2013;35:562–8
   PubMedGoogle Scholar
• Münzker J, Hofer D, Trummer C, et al. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary. J Clin Endocrinol Metab 2015;100:653–60
   PubMed Web of Science ®Google Scholar
• Salameh WA, Redor-Goldman MM, Clarke NJ, et al. Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria. Fertil Steril 2014;101:1135–41.e2
   PubMed Web of Science ®Google Scholar
• Wu H, Ruan X, Jin J, Mueck AO. Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes. Gynecol Endocrinol 2015;31:548–51
   PubMed Web of Science ®Google Scholar
• Choo V. WHO reassesses appropriate body-mass index for Asian populations. Lancet 2002;360:235
   PubMed Web of Science ®Google Scholar
• Wang Q, Guo T, Tao Y, et al. Association between serum adipocyte factor level and insulin resistance in polycystic ovarian syndrome. Gynecol Endocrinol 2011;27:931–4
   PubMed Web of Science ®Google Scholar
• Thessalonkik ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008;89:505–22
   PubMed Web of Science ®Google Scholar
• Dewailly D, Catteau-Jonard S, Reyss AC, et al. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metab 2006;91:3922–7
   PubMed Web of Science ®Google Scholar
• Welt CK, Gudmundsson JA, Arason G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic feature. J Clin Endocrinol Metab 2006;91:4842–8
   PubMed Web of Science ®Google Scholar
• Guastella E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 2010;94:2197–201
   PubMed Web of Science ®Google Scholar
• Li RJ, Qiu SD, Wang HX, et al. Androgen receptor: a new player associated with apoptosis and proliferation of pancreatic beta cell in type 1 diabetes mellitus. Apoptosis 2008;13:959–71
   PubMed Web of Science ®Google Scholar
• Wierman ME. Sex steroid effects at target tissues: mechanisms of action. Adv Physiol Educ 2007;31:26–33
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036–41
   PubMed Web of Science ®Google Scholar
• Chu MC, Cosper P, Orio F, et al. Insulin resistance in postmenopausal women with metabolic syndrome and the measurements of adiponectin, leptin, and ghrelin. Am J Obestet Gynecol 2006;194:100–4
   PubMed Web of Science ®Google Scholar
• Ozegowska KE, Pawelczyk LA. The role of insulin and selected adipocytokines in patients with polycystic ovary syndrome (PCOS) – a literature review. Ginekol Pol 2015;86:300–4
   PubMed Web of Science ®Google Scholar
• Kauffman RP, Baker TE, Baker VM, et al. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. Am J Obstet Gynecol 2008;198:670.e1–7; discussion 670.e7–10
   PubMed Web of Science ®Google Scholar
• Tsai YH, Wang TW, Wei HJ, et al. Dietary intake, glucose metabolism, and sex hormones in women with polycystic ovary syndrome (PCOS) compared with women with non-PCOS-related infertility – CORRIGENDUM. Br J Nutr 2014;20:1
   Google Scholar
• Chun S. Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Mullerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome. Clin Exp Reprod Med 2014;41:86–91
   PubMedGoogle Scholar
• Ebrahimi-Mamaghani M, Saghafi-Asl M, Pirouzpanah S, et al. Association of insulin resistance with lipid profile, metabolic syndrome, and hormonal aberrations in overweight or obese women with polycystic ovary syndrome. J Health Popul Nutr 2015;33:157–67
   PubMed Web of Science ®Google Scholar
• Shah PK. Atherosclerosis: targeting endogenous apo A-I – a new approach for raising HDL. Nat Rev Cardiol 2011;8:187–8
   PubMed Web of Science ®Google Scholar